“We intend to establish Takeda India as a CoE in clinical research”
Bio Spectrum|June 2020
Japanese multinational pharmaceutical company Takeda announced the appointment of Koki Sato as the Head for the company’s India business on April 1, 2020. Sato has been a part of Takeda since 2003 and has grown within the company to hold various senior international roles across multiple functions, including commercial operations, finance, and HR. Prior to this role, he was the General Manager of Ukraine, Belarus, and Moldova (UBM) Cluster in Takeda’s ICMEA (India, C.I.S., Middle East, Turkey, and Africa) area. BioSpectrum India took this opportunity to interact with Koki Sato, General Manager (GM), Takeda Pharmaceuticals India Pvt. Ltd to find out more about the growth of the India business at Takeda.
Dr Manbeena Chawla
“We intend to establish Takeda India as a CoE in clinical research”

How has been the growth of Takeda India since its inception in 2011? What changes are you planning to bring under your leadership?

Takeda has been steadily growing in the country since 2011. Takeda expanded its footprint and portfolio in India with the acquisition of Shire Pharmaceuticals in 2019. In FY 2019, Takeda India achieved a strong double-digit growth with the team’s relentless commitment to patients and business. Our immunology and haematology businesses have led our growth across the country and have maintained their leadership positions in the market. We also launched our genetic disease (GD) portfolio to augment our commitment to patients suffering from rare diseases in India. As we move forward, our vision is to increase momentum in serving the patient needs through our innovative therapies. We have a strong Access to Medicine (AtM) strategy that is fundamental to our philosophy to address the broader structural barriers that prevent patients in underserved communities from receiving the care and treatment they deserve. With my appointment, I will look at supporting the team in India to further bolster our commitment to patients, build trust with the key stakeholders across the ecosystem, strengthen our reputation in the country and drive the business to newer heights.

What are the major initiatives in store to ensure affordable and accessible healthcare delivery in India?

Denne historien er fra June 2020-utgaven av Bio Spectrum.

Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.

Denne historien er fra June 2020-utgaven av Bio Spectrum.

Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.

FLERE HISTORIER FRA BIO SPECTRUMSe alt
Economic Survey Lays Focus On Mental Healthcare For The First Time
Bio Spectrum

Economic Survey Lays Focus On Mental Healthcare For The First Time

For the first time ever, the Economic Survey 2023-24 tabled by the Union Minister of Finance and Corporate Affairs Nirmala Sitharaman in Parliament recently, talks extensively about mental health, its significance and implications on policy recommendations.

time-read
1 min  |
September 2024
IIT-G discovers RNA-destroying function of p30 protein in African Swine Fever Virus
Bio Spectrum

IIT-G discovers RNA-destroying function of p30 protein in African Swine Fever Virus

Indian Institute of Technology Guwahati (IIT-G) researchers have investigated the biochemistry of the African Swine Fever Virus (ASFV) protein, focusing on understanding the biochemical processes of infection to devise effective control strategies.

time-read
1 min  |
September 2024
13th Bengaluru INDIA NANO 2024 brings together 1018 delegates, 3,000+ visitors
Bio Spectrum

13th Bengaluru INDIA NANO 2024 brings together 1018 delegates, 3,000+ visitors

The 13th edition of Bengaluru INDIA NANO 2024, organised by the Department of Science & Technology, Government of Karnataka, Karnataka Science & Technology Promotion Society (KSTePS), and Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR) concluded on August 3 with participation of 1018 delegates, 11 countries including Korea, Morocco, USA, UK, France, Canada, Germany, Netherlands, Russia, Japan, and Poland, 49 exhibitors comprising 21 startups and 28 industry and institutes, and 200 posters. The exhibition had a footfall of 3,000+ visitors.

time-read
3 mins  |
September 2024
Are Nutraceuticals DRUGS? Examining a Needless Regulatory Tussle
Bio Spectrum

Are Nutraceuticals DRUGS? Examining a Needless Regulatory Tussle

The news has been around for a while which has put a big question mark ahead of the Indian nutraceuticals industry.

time-read
9 mins  |
September 2024
Can India Reclaim API Throne from China?
Bio Spectrum

Can India Reclaim API Throne from China?

Despite having the third-largest pharmaceutical industry by volume in the world and being the largest manufacturer of generic medicines globally, India is heavily dependent on China for imports of raw materials, Key Starting Materials (KSMs), and Active Pharmaceutical Ingredients (APIs).

time-read
10+ mins  |
September 2024
JRS Pharma & Gujarat Microwax open new manufacturing facility in Mehsana
Bio Spectrum

JRS Pharma & Gujarat Microwax open new manufacturing facility in Mehsana

JRS Pharma, a leading manufacturer of excipients, in partnership with Gujarat Microwax, has commissioned a new manufacturing facility for cotton-based croscarmellose sodium.

time-read
1 min  |
September 2024
NovaLead's patented repurposed drug for treating DFU gets CDSCO approval
Bio Spectrum

NovaLead's patented repurposed drug for treating DFU gets CDSCO approval

Pune-based NovaLead Pharma has announced that the drug regulator in India, Central Drugs Standard Control Organisation (CDSCO), has approved their patented Repurposed Drug for treatment of Diabetic Foot Ulcer (DFU) which is a global unmet medical need.

time-read
1 min  |
September 2024
Medicamen Organics expands footprint in East Africa with $75,000 investment in Rwanda
Bio Spectrum

Medicamen Organics expands footprint in East Africa with $75,000 investment in Rwanda

Delhi-based pharma company Medicamen Organics has taken a significant step in its global expansion strategy by signing a Memorandum of Understanding (MoU) with Depot Pharmacy Yego in Rwanda.

time-read
1 min  |
September 2024
Mankind Pharma acquires 100% stake in Bharat Serums and Vaccines for Rs 13,630 Cr
Bio Spectrum

Mankind Pharma acquires 100% stake in Bharat Serums and Vaccines for Rs 13,630 Cr

Mankind Pharma has entered into a definitive agreement to acquire a 100 per cent stake in Bharat Serums and Vaccines Limited (BSV) from Advent International, for an enterprise value of approx.

time-read
1 min  |
September 2024
Thyrocare buys Polo Labs' pathology diagnostic biz to strengthen Northern India presence
Bio Spectrum

Thyrocare buys Polo Labs' pathology diagnostic biz to strengthen Northern India presence

Mumbai-based Thyrocare, a leading diagnostic and preventive healthcare service provider in India, has entered into a Business Transfer Agreement with Polo Labs to acquire their pathology diagnostic business.

time-read
1 min  |
September 2024